Related Experiment Video
Updated: Aug 11, 2026
Intracameral Injection in Rats with Low Risk of Adverse Effects
Published on: May 31, 2024
[Sub-Tenon's injection of triamcinolone acetonide for choroidal neovascularization]
Aya Kim1, Fumi Gomi, Hirokazu Sakaguchi
1Department of Ophthalmology, Osaka University Hospital, Suita, Japan. aya.kimu@mhc.west.ntt.co.jp
Purpose:
To evaluate the efficacy of sub-Tenon's injection of triamcinolone acetonide for age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
Method:
Sub-Tenon's injection of triamcinolone acetonide was performed in patients (27 eyes) with the subfoveal choroidal neovascularization of AMD and in patients (10 eyes) with PCV, and its efficacy was evaluated. The visual acuity and the exudation from lesions evaluated by fluorescein angiography or optical coherence tomography (OCT) at three months or six months after injection were compared to the baseline values.
Results:
Visual acuity was maintained in 23 of the 27 eyes (85.0%) with AMD and in 8 of the 10 eyes (80.0%) with PCV at three months after injection. Six months after infusion, the rate declined to 76.0% and 66.7%, respectively. Exudation from lesions had decreased in 10 eyes of 25 eyes(40.0%) with AMD and in 2 eyes of 9 eyes (22.2%) with PCV by six months after injection. Complete suppression of the lesions was observed in seven eyes (18.9%) with relatively small lesions.
Conclusion:
Sub-Tenon's injection of triamcinolone acetonide is useful as a treatment modality for AMD and PCV.
